← boardnext 2026-08
BIVI
BioVie Inc.distress 6/10 · elevated risk$1.340%today-85% from 52w high
Infectious Disease 1Neurology 1
Lead: Long COVID
Revenue
pre-revenue
Liquidity
$13M
Runway
0.5 yrs
Shares 1y
+0%
Price & events
+7.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-22.1%
1W
-30.9%
1M
-6.3%
3M
+9.8%
6M
-83.7%
1Y
-96.5%
2Y
-99.9%
5Y
-99.9%
All
Overview
- Market Cap
- $10.11M
- Volume
- 597
- 52 Week Range
- $1.06 – $8.99
- Total Shares
- 7.54M
- Float Shares
- 7.50M
- Short %
- 5.98%
- % Held by Insiders
- 0.36%
- % Held by Institutions
- 13.94%
- RVOL
- 0.00x
- Beta
- 0.57
Pipeline stages · 1 programs
NE3107
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
Catalyst news & presentations · 1
- 2026-08-24earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 7,541,839 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-07-01ThinkEquityBuy
Recent news
- 2026-07-17[S-1] BIOVIE INC. Files IPO Registration Statement - Stock Titan
- 2026-07-16Enterprise value to EBIT forward of BioVie Inc. – NASDAQ:BIVIW - TradingView
- 2026-07-15บทสัมภาษณ์ของ Foremost Clean Energy และ BioVie เตรียมออกอากาศในรายการ RedChip Small Stocks, Big Money(TM) ทางสถานีโทรทัศน์ Bloomberg TV - Moomoo
- 2026-07-14BioVie Inc. Warrants (BIVIW) Trade Flat Near Key Levels – What to Watch - Hedge Fund Favorites - dars.gov.et
- 2026-07-08Enterprise value to revenue forward of BioVie Inc. – NASDAQ:BIVI - TradingView
- 2026-06-30BIOVIE INC. SEC Filing (Jun 30, 2026) - Stock Titan
- 2026-06-26BioVie Inc. Class A Actuals & Estimates (NASDAQ:BIVI) - TradingView
- 2026-06-25BIVI Forecast — Price Target — Prediction for 2027 - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.